The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status
Aims: The activation of the Wnt/ ß-catenin signaling pathway has been demonstrated to play a crucial role in the development of myeloid neoplasms. In addition to CD34, which has been used until now in the diagnosis and staging of clonal hematopoietic diseases, Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN), CD117, which has found its place in hematopoietic diseases, also provides significant benefits in these respects. In this study, we evaluated the immunohistochemical presence and utility of ß-catenin in blasts relative to other markers, as the inhibition of ß-catenin activity may be an attractive therapeutic approach
Methods: By retrospectively analyzing bone marrow samples with ß-catenin immune marker, we determined the staining rates, intensities, and patterns of 30 MDS, 29 MPN cases and 30 normal bone marrow controls, in comparison to the efficacy of the the well-known CD34 and CD117. We statistically interpreted the correlation between them.
Results: Based on the findings, ß-catenin, which has recently been used in hematopoietic diseases and is said to have a high efficacy in acute myeloid leukemia (AML) cases, was not immunohistochemically detectable in our study. As expected, CD34 and CD117 immun markers exhibited significant blast staining. MPN cases were more prone to staining with CD117.
Conclusion: CD34 continues to be the most reliable marker for identifying blasts for diagnosing and grading bone marrow neoplasms while CD117 may have a supportive role in this process. Further investigation is required to ascertain the true effectiveness of ß-catenin, a molecule that has demonstrated encouraging potential in the context of AML.

1. Delhommeau F, Pisani DF, James C, Casadevall N, ConstantinescuS, Vainchenker W. Oncogenic mechanisms in myeloproliferativedisorders. Cell Mol Life Sci. 2006; 63(24):2939-2953.
2. Li L, Sheng Y, Li W, et al. Beta- catenin is a candidate therapeutic targetfor myeloid neoplasms with del (5 q). Cancer Res. 2017;01:77(15): 4116-4126.
3. Lee JH, List A, Sallman DA. Molecular pathogenesis of myelodysplasticsyndromes with deletion 5q. European Journal of Haematopathology.2019;102(3):203-209.
4. Orazi A, Czader MB. Myelodysplastic syndromes. Am J Clin Pathol.2009;132(2):290-305.
5. George TI, Arber DA. Pathology of the myeloproliferative diseases.Hematology/Oncology Clinics of North America. 2003;17(5):1101-1127.
6. Germing U, Aul C, Niemeyer CM, Haas R, Bennet JM. Epidemiology,classification and prognosis of adults and children with myelodysplasticsyndromes. Ann Haematol. 2008 Sep;87(9):691-699.
7. Min YH, Lee ST, Min DW, et al. CD34 immunohistochemical stainingof bone marrow biopsies in myelodysplastic syndromes. Yonsei Med J.1995;36(1):1-8.
8. Sperling C, Schwartz S, Büchner T, Thiel E, Ludwig WD. Expressionof the stem cell factor receptor c-kit (cd117) in acute leukemias.Haematologica. 1997;82(5):617-621
9. Jindal N, Minhas G, Prabhakar S, Anand A. Characterization of Lin-ve cd34 and cd117 cell population reveals an increased expression inbone marrow derived stem cells. Current Neurovascular Research.2014;11(1):68-74.
10. Guo X, Mak KK, Taketo MM, Yang Y. The Wnt/b-Catenin pathwayinteracts differentially with PTHrP signaling to control chondrocytehypertrophy and final maturation. PLoS ONE. 2009;26;4(6):e6067. doi:10.1371/journal.pone.0006067.
11. Cobas M, Wilson A, Ernst B, et al. Beta-catenin is dispensable forhematopoiesis and lymphopoiesis. J. Exp. Med. J. 2004;19;199(2):221-229.
12. Morin PJ. Beta-catenin signaling and cancer. BioEssays.1999;21(12):1021-1030.
13. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P.Stabilization of β-catenin by genetic defects in melanoma cell lines.Science. 1997; 275(5307):1790-1792.
14. Rask K, Nilsson A, Brannstrom M, et al. Wnt-signalling pathway inovarian epithelial tumours: increased expression of β-catenin andGSK3beta. Br J Cancer. 2003;89(7):1298-1304.
15. Le NH, Franken P, Fodde R. Tumour-stroma interactions in colorectalcancer: converging on β-catenin activation and cancer stemness. BritishJournal of Cancer. 2008;98(12):1886-1893
16. Rebolj K, Veber M, Drobnic M, Malicev E. Hematopoietic stem celland mesenchymal stem cell population size in bone marrow samplesdepends on patient’s age and harvesting technique. Cytotecnology. 2018;70(6):1575-1583.
17. Nomdede´u JF, Mateu R, Alte`s A , et al. Enhanced myeloid specificityof cd 117 compared with cd13 and cd33. Leukemia Research.1999;23(4):341-347
18. Moshaver B, Wouters RF, Kelder A, et al. Relationship between cd34/cd38 and side population (SP) defined leukemia stem cell. LeukemiaResearch. 2019;81:27-34.
19. Muroi K, Amemiya Y, Miura Y. Specificity of cd117 expression in thediagnosis of acute myeloid leukemia. Leukemia. 1996;10(6):1048.
20. Di Noto R, Lo Pardo C, et al. Stem cell factor receptor (c-kit, cd117)is expressed on blast cells from most immature types of acutemyeloid mallignancies but is also a characteristic of a subset of acutepromyelocytic leukaemia. Br J Haematol. 1996;92(3):562-564.
21. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes inmyelodysplasia, cd34 and cd117 expression abnormalities are common.Am J Clin Pathol. 2006;125(6):884-894.
22. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator ofjoint remodeling. Nat. Med. 2007;13(2):156-163
23. Suboticki T, Ajtica OM, Micica M, et al. β-catenin and PPAR-γ levels inbone marrow of myeloproliferative neoplasm: an immunohistochemicaland ultrastructural study. Ultrastructural Pathology. 2018;42(6):498-507. Doi:10.1080/01913123.2018.1558323
24. Jauregui MP, Sanchez SR, Ewton AA, et al. The role of β-cateninin chronic myeloproliferative disorders. Human Pathology. 2008;39(10):1454-1458.
25. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, et al. Clinical significanceof nuclear non-phosphorylated β-catenin in acute myeloid leukaemiaand myelodysplastic syndrome. British Journal of Haematology.2008;140(4):394-401.
26. Ysebaert L, Chicanne G, Demur C, et al. Expression of β-catenin byacute myeloid leukemia cells predicts enhanced clonogenic capacitiesand poor prognosis. Leukemia. 2006;20(7):1211-1216.
Volume 1, Issue 3, 2023
Page : 54-58